{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:39:55Z","timestamp":1791855595439,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tampere University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aimed to summarise the existing knowledge regarding antithrombotic medications following surgical aortic valve replacement (SAVR) using a biological valve prosthesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a meta-analysis of studies that reported the results of using antithrombotic medication to prevent thromboembolic events after SAVR using a biological aortic valve prosthesis and recorded the outcomes 12 months after surgery. Since no randomised controlled trials were identified, observational studies were included. The analyses were conducted separately for periods of 0\u201312 months and 3\u201312 months after surgery. A random effects model was used to calculate pooled outcome event rates and 95% confidence intervals (CIs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The search yielded eight eligible observational studies covering 6727 patients overall. The lowest 0- to 12-month mortality was observed in patients with anticoagulation (2.0%, 95% CI 0.4\u20139.7%) and anticoagulation combined with antiplatelet therapy (2.2%, 95% CI 0.9\u20135.5%), and the highest was in patients without antithrombotic medication (7.3%, 95% CI 3.6\u201314.2%). Three months after surgery, mortality was lower in anticoagulant patients (0.5%, 95% CI 0.1\u20132.6%) than in antiplatelet patients (3.0%, 95% CI 1.2\u20137.4%) and those without antithrombotics (3.5%, 95% CI 1.3\u20139.3%). There was no eligible evidence of differences in stroke rates observed among medication strategies. At 0- to 12-month follow-up, all antithrombotic treatment regimens resulted in an increased bleeding rate (antiplatelet 4.2%, 95% CI 2.9\u20136.1%; anticoagulation 7.5%, 95% CI 3.8\u201314.4%; anticoagulation combined with antiplatelet therapy 8.3%, 95% CI 5.7\u201311.8%) compared to no antithrombotic medication (1.1%, 95% CI 0.4\u20133.4%). At 3- to 12-month follow-up, there was up to an eight-fold increase in the bleeding rate in patients with anticoagulation combined with antiplatelet therapy when compared to those with no antithrombotic medication. Overall, the evidence certainty was ranked as very low.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although this meta-analysis reveals that anticoagulation therapy has a beneficial tendency in terms of mortality at 1 year after biological SAVR and suggests potential advantages in continuing anticoagulation beyond 3 months, it is limited by very low evidence certainty. The imperative for cautious interpretation and the urgent need for more robust randomised research underscore the complexity of determining optimal antithrombotic strategies in this patient population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13019-024-02863-z","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T08:02:25Z","timestamp":1719388945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic management after aortic valve replacement with biological prosthesis: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Mikko","family":"Uimonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilari","family":"Kuitunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Ponkilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Mennander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko S.","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"2","key":"2863_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1010-7940(01)01099-5","volume":"21","author":"D Paparella","year":"2002","unstructured":"Paparella D, Yau T, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. European journal of cardio-thoracic surgery. Eur J Cardiothorac Surg. 2002;21(2):232\u201344.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"8","key":"2863_CR2","doi-asserted-by":"publisher","first-page":"S272","DOI":"10.1097\/PCC.0000000000000759","volume":"17","author":"RA Bronicki","year":"2016","unstructured":"Bronicki RA, Hall M. Cardiopulmonary bypass-induced inflammatory response: pathophysiology and treatment. Pediatr Crit Care Med. 2016;17(8):S272\u20138.","journal-title":"Pediatr Crit Care Med."},{"issue":"3","key":"2863_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1378\/chest.112.3.676","volume":"112","author":"S Wan","year":"1997","unstructured":"Wan S, LeClerc J-L, Vincent J-L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997;112(3):676\u201392.","journal-title":"Chest."},{"issue":"1","key":"2863_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bpa.2009.09.012","volume":"24","author":"VG Nielsen","year":"2010","unstructured":"Nielsen VG, Asmis LM. Hypercoagulability in the perioperative period. Best Pract Res Clin Anaesthesiol. 2010;24(1):133\u201344.","journal-title":"Best Pract Res Clin Anaesthesiol."},{"issue":"3","key":"2863_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/ejcts\/ezr001","volume":"41","author":"S Rafiq","year":"2012","unstructured":"Rafiq S, Johansson PI, Ostrowski SR, Stissing T, Steinbr\u00fcchel DA. Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome. Eur J Cardiothorac Surg. 2012;41(3):550\u20135.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"3","key":"2863_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0022-5223(19)34748-8","volume":"104","author":"E Eybl","year":"1992","unstructured":"Eybl E, Grimm M, Grabenw\u00f6ger M, B\u00f6ck P, M\u00fcller MM, Wolner E. Endothelial cell lining of bioprosthetic heart valve materials. J Thorac Cardiovasc Surg. 1992;104(3):763\u20139.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"6","key":"2863_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/039139889401700606","volume":"17","author":"T Fischlein","year":"1994","unstructured":"Fischlein T, Lehner G, Lante W, Fittkau M, Murphy J, Weinhold C, et al. Endothelialization of cardiac valve bioprostheses. Int J Artif Organs. 1994;17(6):345\u201352.","journal-title":"Int J Artif Organs."},{"issue":"7","key":"2863_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;43(7):561\u2013632.","journal-title":"Eur Heart J."},{"issue":"4","key":"2863_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","volume":"77","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP III, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):450\u2013500.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"2863_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejcts.2007.03.031","volume":"32","author":"M Brueck","year":"2007","unstructured":"Brueck M, Kramer W, Vogt P, Steinert N, Roth P, G\u00f6rlach G, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg. 2007;32(1):108\u201312.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"19 Suppl","key":"2863_CR11","first-page":"II95","volume":"98","author":"K Moinuddeen","year":"1998","unstructured":"Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G, et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation. 1998;98(19 Suppl):II95-8 discussion II8.","journal-title":"Circulation"},{"key":"2863_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1\u20139.","journal-title":"Syst Rev."},{"issue":"10","key":"2863_CR13","first-page":"ED000142","volume":"2019","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;2019(10):ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2863_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156(8):787\u20138.","journal-title":"JAMA Surg."},{"issue":"4","key":"2863_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"2863_CR16","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, McAleenan A, Reeves BC, Higgins JP. Assessing risk of bias in a non\u2010randomized study. Cochrane handbook for systematic reviews of interventions. 2019:621\u201341.","DOI":"10.1002\/9781119536604.ch25"},{"key":"2863_CR17","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ."},{"issue":"1","key":"2863_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synthesis Methods. 2021;12(1):55\u201361.","journal-title":"Res Synthesis Methods."},{"key":"2863_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjcard.2020.05.018","volume":"129","author":"AA Gryaznov","year":"2020","unstructured":"Gryaznov AA, Saeyeldin A, Abdelbaky M, Zafar MA, Tanweer M, Papanikolaou D, et al. Nonusefulness of antithrombotic therapy after surgical bioprosthetic aortic valve replacement. Am J Cardiol. 2020;129:71\u20138.","journal-title":"Am J Cardiol."},{"issue":"2","key":"2863_CR20","first-page":"139","volume":"25","author":"T Owais","year":"2016","unstructured":"Owais T, Rouman M, Breuer M, H\u00fcter L, Fuchs J, Lauer B, et al. Anticoagulation after biological aortic valve replacement: is there an optimal regimen. J Heart Valve Dis. 2016;25(2):139\u201344.","journal-title":"J Heart Valve Dis."},{"issue":"20","key":"2863_CR21","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1001\/jama.2012.54506","volume":"308","author":"C M\u00e9rie","year":"2012","unstructured":"M\u00e9rie C, K\u00f8ber L, Olsen PS, Andersson C, Gislason G, Jensen JS, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308(20):2118\u201325.","journal-title":"JAMA."},{"issue":"11_suppl_1","key":"2863_CR22","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1161\/CIRCULATIONAHA.111.084772","volume":"126","author":"T Al-Atassi","year":"2012","unstructured":"Al-Atassi T, Lam K, Forgie M, Boodhwani M, Rubens F, Hendry P, et al. Cerebral microembolization after bioprosthetic aortic valve replacement: comparison of warfarin plus aspirin versus aspirin only. Circulation. 2012;126(11_suppl_1):S239\u201344.","journal-title":"Circulation"},{"issue":"5","key":"2863_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jtcvs.2012.01.024","volume":"144","author":"A Weber","year":"2012","unstructured":"Weber A, Noureddine H, Englberger L, Dick F, Gahl B, Aymard T, et al. Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J Thoracic Cardiovasc Surg. 2012;144(5):1075\u201383.","journal-title":"J Thoracic Cardiovasc Surg."},{"issue":"1","key":"2863_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1010-7940(97)00306-0","volume":"13","author":"J Ninet","year":"1998","unstructured":"Ninet J, Tronc F, Robin J, Curtil A, Aleksic I, Champsaur G. Mechanical versus biological isolated aortic valvular replacement after the age of 70: equivalent long-term results. Eur J Cardiothorac Surg. 1998;13(1):84\u20139.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"04","key":"2863_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-0037-1602825","volume":"66","author":"S Alex","year":"2018","unstructured":"Alex S, Hiebert B, Arora R, Menkis A, Shah P. Survival and long-term outcomes of aortic valve replacement in patients aged 55 to 65 years. Thoracic Cardiovasc Surg. 2018;66(04):313\u201321.","journal-title":"Thoracic Cardiovasc Surg."},{"issue":"3","key":"2863_CR26","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jtcvs.2018.11.129","volume":"158","author":"H Amrane","year":"2019","unstructured":"Amrane H, Deeb GM, Popma JJ, Yakubov SJ, Gleason TG, Van Mieghem NM, et al. Causes of death in intermediate-risk patients: the randomized surgical replacement and transcatheter aortic valve implantation trial. J Thoracic Cardiovasc Surg. 2019;158(3):718-28.e3.","journal-title":"J Thoracic Cardiovasc Surg."},{"issue":"6","key":"2863_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jtcvs.2016.11.069","volume":"153","author":"V Gaudiani","year":"2017","unstructured":"Gaudiani V, Deeb GM, Popma JJ, Adams DH, Gleason TG, Conte JV, et al. Causes of death from the randomized CoreValve US pivotal high-risk trial. J Thoracic Cardiovasc Surg. 2017;153(6):1293-301.e1.","journal-title":"J Thoracic Cardiovasc Surg."},{"issue":"5","key":"2863_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jacc.2014.11.027","volume":"65","author":"M Urena","year":"2015","unstructured":"Urena M, Webb JG, Eltchaninoff H, Mu\u00f1oz-Garc\u00eda AJ, Bouleti C, Tamburino C, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol. 2015;65(5):437\u201348.","journal-title":"J Am Coll Cardiol."},{"issue":"02","key":"2863_CR29","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.4244\/EIJ-D-16-00558","volume":"13","author":"LE Dobson","year":"2017","unstructured":"Dobson LE, Musa TA, Uddin A, Fairbairn TA, Swoboda PP, Ripley DP, et al. Post-procedural myocardial infarction following surgical aortic valve replacement and transcatheter aortic valve implantation. EuroIntervention. 2017;13(02):e153\u201360.","journal-title":"EuroIntervention."},{"issue":"7","key":"2863_CR30","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.amjcard.2014.06.032","volume":"114","author":"WT O'Neal","year":"2014","unstructured":"O\u2019Neal WT, Shah AJ, Efird JT, Rautaharju PM, Soliman EZ. Subclinical myocardial injury identified by cardiac infarction\/injury score and the risk of mortality in men and women free of cardiovascular disease. Am J Cardiol. 2014;114(7):1018\u201323.","journal-title":"Am J Cardiol."},{"issue":"3","key":"2863_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.7812\/TPP\/11-082","volume":"15","author":"JT Levis","year":"2011","unstructured":"Levis JT, Schultz G, Lee PC. Acute myocardial infarction due to coronary artery embolism in a patient with a tissue aortic valve replacement. Permanente J. 2011;15(3):82.","journal-title":"Permanente J."},{"issue":"22","key":"2863_CR32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, De Barros e Silva PG, Liporace IL, Sampaio RO, Tarasoutchi, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Eng J Med. 2020;383(22):2117\u201326.","journal-title":"N Eng J Med"},{"key":"2863_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.thromres.2016.11.021","volume":"150","author":"S Rafiq","year":"2017","unstructured":"Rafiq S, Steinbr\u00fcchel DA, Lille\u00f8r NB, M\u00f8ller CH, Lund JT, Thiis JJ, et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thrombosis Res. 2017;150:104\u201310.","journal-title":"Thrombosis Res."},{"issue":"5","key":"2863_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/01.CIR.0000137122.95108.52","volume":"110","author":"T Gherli","year":"2004","unstructured":"Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110(5):496\u2013500.","journal-title":"Circulation."},{"issue":"6","key":"2863_CR35","first-page":"667","volume":"16","author":"A Colli","year":"2007","unstructured":"Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic\u2122 heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16(6):667.","journal-title":"J Heart Valve Dis"},{"issue":"7368","key":"2863_CR36","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/bmj.325.7368.828","volume":"325","author":"DA Fitzmaurice","year":"2002","unstructured":"Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325(7368):828\u201331.","journal-title":"BMJ."},{"issue":"4","key":"2863_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1503\/cmaj.070186","volume":"177","author":"JA Delaney","year":"2007","unstructured":"Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug\u2013drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177(4):347\u201351.","journal-title":"CMAJ."}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02863-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-024-02863-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02863-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T08:06:58Z","timestamp":1719389218000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-024-02863-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2863"],"URL":"https:\/\/doi.org\/10.1186\/s13019-024-02863-z","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}